Metastatic Melanoma Clinical Trials

49 recruiting

Metastatic Melanoma Trials at a Glance

53 actively recruiting trials for metastatic melanoma are listed on ClinicalTrialsFinder across 6 cities in 19 countries. The largest study group is Phase 2 with 23 trials, with the heaviest enrollment activity in Los Angeles, New York, and Pittsburgh. Lead sponsors running metastatic melanoma studies include Iovance Biotherapeutics, Inc., M.D. Anderson Cancer Center, and Institute of Oncology Ljubljana.

Browse metastatic melanoma trials by phase

Treatments under study

About Metastatic Melanoma Clinical Trials

Looking for clinical trials for Metastatic Melanoma? There are currently 49 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Melanoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Melanoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 53 trials

Recruiting
Phase 1Phase 2

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma+10 more
National Cancer Institute (NCI)16 enrolled26 locationsNCT05896839
Recruiting
Phase 2

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Head and Neck Squamous Cell Carcinoma+22 more
National Cancer Institute (NCI)150 enrolled221 locationsNCT05136196
Recruiting
Phase 1Phase 2

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Lung CancerMelanomaMetastatic Lung Cancer+2 more
Obsidian Therapeutics, Inc.208 enrolled9 locationsNCT06060613
Recruiting
Phase 4

ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

Metastatic MelanomaAdvanced Melanoma
NYU Langone Health90 enrolled1 locationNCT07504796
Recruiting

Generation of an Artificial Intelligence Algorithm Based on the Analysis of Melanoma Peri-scar Dermatoheliosis, as a Predictive Factor of Response to Anti-PD-1

Metastatic Melanoma
Nantes University Hospital700 enrolled20 locationsNCT05856565
Recruiting
Phase 2

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic MelanomaPathologic Stage IV Cutaneous Melanoma AJCC v8
M.D. Anderson Cancer Center35 enrolled1 locationNCT05026983
Recruiting
Phase 3

Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Unresectable/Metastatic Melanoma
Canadian Cancer Trials Group614 enrolled30 locationsNCT02821013
Recruiting
Not Applicable

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

Metastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic Renal Cell Carcinoma+15 more
M.D. Anderson Cancer Center40 enrolled1 locationNCT04693377
Recruiting
Phase 2

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell CarcinomaMetastatic Melanoma
Providence Health & Services92 enrolled1 locationNCT05913388
Recruiting
Phase 3

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Lung Non-Small Cell Carcinoma+7 more
NRG Oncology269 enrolled263 locationsNCT06500455
Recruiting
Phase 3

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

MelanomaMetastatic MelanomaUnresectable Melanoma
Iovance Biotherapeutics, Inc.670 enrolled75 locationsNCT05727904
Recruiting
Phase 1

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Lung Non-Small Cell CarcinomaMetastatic Melanoma+7 more
M.D. Anderson Cancer Center75 enrolled1 locationNCT03025256
Recruiting
Phase 1Phase 2

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

Metastatic MelanomaLiver Metastases
University of Wisconsin, Madison15 enrolled1 locationNCT07281924
Recruiting
Phase 1

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Breast CancerHead and Neck Squamous Cell CarcinomaMetastatic Malignant Solid Neoplasm+14 more
Anusha Kalbasi18 enrolled3 locationsNCT04119024
Recruiting
Phase 1Phase 2

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Metastatic MelanomaMelanoma Stage IVMelanoma Stage III+1 more
Perspective Therapeutics300 enrolled13 locationsNCT05655312
Recruiting
Phase 1Phase 2

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Phase 1

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic MelanomaClinical Stage I Cutaneous Melanoma AJCC v8+6 more
Carlo Contreras36 enrolled1 locationNCT04697576
Recruiting
Not Applicable

Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma

Metastatic MelanomaOligoProgressive Metastatic Disease
University Health Network, Toronto52 enrolled1 locationNCT07112170
Recruiting
Phase 2

Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma

Advanced or Metastatic Melanoma
Hanmi Pharmaceutical Company Limited45 enrolled10 locationsNCT07449754
Recruiting
Phase 2

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8+26 more
M.D. Anderson Cancer Center50 enrolled1 locationNCT04771520